EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of prior use of antiplatelets on COVID-19 susceptibility, progression, and severity: a population-based study

Ángela Prieto-Campo, Maruxa Zapata-Cachafeiro, Manuel Portela-Romero, María Piñeiro-Lamas, Adolfo Figueiras, Ángel Salgado-Barreira

Revista Española de Cardiología (English Edition) · 2024

DOI: 10.1016/j.rec.2023.12.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Revista Española de Cardiología (English Edition), 2024. Verfasst von Ángela Prieto-Campo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Salud Pública, Facultad de Farmacia, Universidad de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain. Hauptthemen laut MEDLINE: COVID-19, Platelet Aggregation Inhibitors, Disease Progression, Hospitalization. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Regional Development Fund, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION AND OBJECTIVES: Hypercoagulability and thromboembolism are processes that arise from severe acute respiratory syndrome coronavirus 2 infection and are responsible for a high degree of coronavirus disease 2019 (COVID-19)-related morbidity and mortality. This study sought to assess the effect of antiplatelet drugs on COVID-19 severity (risk of hospitalization and mortality), susceptibility to severe acute respiratory syndrome coronavirus 2 infection, and progression to severe COVID-19. METHODS: We conducted a population-based case-control study in a northwestern region of Spain in 2020. The study involved 3060 participants with a positive polymerase chain reaction test who were hospitalized, 26 757 participants with a positive polymerase chain reaction test who were not hospitalized, and 56 785 healthy controls. RESULTS: Triflusal seemed to be associated with a significant increase in risk of hospitalization (aOR, 1.97; 95%CI, 1.27-3.04) and susceptibility to infection (OR, 1.45; 95%CI, 1.07-1.96). It also appeared to lead to a nonsignificant increase in the risk of mortality (OR, 2.23; 95%CI, 0.89-5.55) and/or progression to more severe disease stages (OR, 1.42; 95%CI, 0.8-2.51). Aspirin seemed to be associated with a statistically significant decrease in susceptibility to severe acute respiratory syndrome coronavirus 2 infection (OR, 0.92; 95%CI, 0.86-0.98). CONCLUSIONS: Triflusal use appears to increase the risk of susceptibility to COVID-19 infection and an even higher risk of hospitalization, whereas the other antiplatelets could be associated with a reduction in the risk of the various outcomes or have no effect on risk. These findings could support reconsideration of triflusal prescription in COVID-19 pandemic situations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Platelet Aggregation InhibitorsDisease ProgressionHospitalizationSeverity of Illness IndexHumansMaleFemaleSpainCase-Control StudiesMiddle AgedAgedSARS-CoV-2Disease SusceptibilityCOVID-19 Drug TreatmentSalicylatesAdultAspirin

Stichwörter der Autor:innen

AspirinCOVID-19Case-control studyEstudio de casos y controlesInhibidores de la agregación plaquetariaPlatelet aggregation inhibitorsTriflusalÁcido acetilsalicílico

Substanzen

Platelet Aggregation InhibitorstriflusalSalicylatesAspirin

Autor:innen und Institutionen

  • Departamento de Salud Pública, Facultad de Farmacia, Universidad de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain.
  • Departamento de Salud Pública, Facultad de Farmacia, Universidad de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain; Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP…
  • Centro de Salud Concepción Arenal, Santiago de Compostela, A Coruña, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain.
  • Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Spain; Institute of Health Research of Santiago de Compostela (IDIS), Santiago de Compostela, A Coruña, Spain.

Förderung

  • European Regional Development Fund
  • Instituto de Salud Carlos III

Zitieren

APA

Prieto-Campo, Á., Zapata-Cachafeiro, M., Portela-Romero, M., Piñeiro-Lamas, M., Figueiras, A., & Salgado-Barreira, Á. (2024). Impact of prior use of antiplatelets on COVID-19 susceptibility, progression, and severity: a population-based study. Revista Española de Cardiología (English Edition). https://doi.org/10.1016/j.rec.2023.12.004

Vancouver

Prieto-Campo Á, Zapata-Cachafeiro M, Portela-Romero M, Piñeiro-Lamas M, Figueiras A, Salgado-Barreira Á. Impact of prior use of antiplatelets on COVID-19 susceptibility, progression, and severity: a population-based study. Revista Española de Cardiología (English Edition). 2024. doi:10.1016/j.rec.2023.12.004

BibTeX
@article{PrietoCampo2024,
  author = {Prieto-Campo, Ángela and Zapata-Cachafeiro, Maruxa and Portela-Romero, Manuel and Piñeiro-Lamas, María and Figueiras, Adolfo and Salgado-Barreira, Ángel},
  title = {Impact of prior use of antiplatelets on COVID-19 susceptibility, progression, and severity: a population-based study},
  journal = {Revista Española de Cardiología (English Edition)},
  year = {2024},
  doi = {10.1016/j.rec.2023.12.004}
}
Kostenlos starten →